Been watching something interesting unfold in the markets lately, and it's worth paying attention to. You've got Meta and Rocket Lab posting killer numbers, stocks near all-time highs, yet their top executives are dumping shares left and right. On the surface, it looks like they know something we don't. But here's where it gets interesting—while these insiders are cashing out, Wall Street institutions are quietly buying up the same stocks like there's no tomorrow.

Let me break down what's actually happening, because it's a masterclass in how to sell shares strategically without triggering panic.

Most of these executive sales aren't random. They're happening through Rule 10b5-1 trading plans—basically pre-scheduled automation that locks in sale dates months in advance. It's legal protection. Executives can't just wake up and dump stock because they heard bad news; the sale was predetermined. Add to that, these people are paid almost entirely in stock. For them, selling is the only way to convert paper wealth into actual cash for taxes, real estate, or portfolio diversification. When your net worth is tied up in company shares and the stock's crushing it near all-time highs, locking in gains is just smart financial planning.

Take Meta. CFO Susan Li sold roughly $35 million in February alone. COO Javier Olivan followed suit. Eight insiders sold over the last 12 months—zero insider buys. Sounds bearish, right? Wrong. The institutional money tells a completely different story. Over the last year, institutions poured over $100 billion into Meta stock. Billionaire investor Bill Ackman reportedly built a multi-billion-dollar position, arguing the company's still undervalued despite the rally.

Why? Because they're looking at fundamentals, not optics. Meta just reported earnings per share of $8.88 in late January, crushing estimates of $8.16. Revenue climbed 23.8% year-over-year. Margins stayed above 30% even with massive AI infrastructure spending. At a P/E of roughly 27.90, that's reasonable valuation for a company growing revenue over 20%. For institutional investors, Meta's a cash machine with a dominant market position. They're not buying at a peak—they're buying a stepping stone to higher valuations.

Now look at Rocket Lab. This one's even more dramatic. Stock went from $14 to over $70 in a year. CEO Peter Beck sold $140 million in December. CFO Adam Spice dumped over $100 million in January. These are life-changing numbers for founders and early executives who built the company from startup to $37 billion titan. After a 400% run-up, taking chips off the table isn't a lack of faith—it's realizing past success. If they thought the company was doomed, they would've sold much earlier at lower prices.

But here's the thing: institutional ownership in Rocket Lab surged to nearly 72%. Institutions bought $4.96 billion in shares while selling only $1.51 billion over 12 months. Vanguard, Baillie Gifford—they're absorbing the supply from insiders. And they're doing it for concrete reasons. Rocket Lab's sitting on a $1.85 billion backlog, much of it from government contracts with the Space Development Agency. That's revenue visibility for years. The company closed 2025 with record $602 million in revenue. Even the Neutron rocket delay to Q4 2026 hasn't deterred accumulation—analysts see it as a temporary bump, not a fundamental problem.

The real insight here is that we're watching a wealth transfer in real time. Insiders are cashing out on the growth of the past decade. Institutions are positioning for the growth of the next decade. Executives sell for personal reasons. Institutions buy for profit. When you understand how to sell shares strategically—through pre-planned mechanisms, at market peaks, for portfolio diversification—you realize insider selling isn't a warning signal. It's just math.

For long-term investors, the takeaway's straightforward. Meta's AI fatigue narrative looks like noise given the institutional support base. Rocket Lab's backlog and space economy dominance outweigh insider selling optics. The real money's betting the rallies are far from over. Following institutional capital often tells you way more than watching a few executives execute pre-planned tax moves.